MAPS Americas 2026 reinforced a structural shift in what medical affairs is expected to deliver: not activity at scale, but measurable contribution to outcomes, while maintaining scientific leadership, stakeholder trust, and compliant collaboration across the enterprise. The meeting’s most consistent signal was that the next phase of transformation will be won through operating model choices : how medical affairs defines value, governs emerging tools and channels (especially AI), orchestrates engagement across touchpoints, and turns stakeholder input into decision-grade insight.
Why MAPS 2026 matters for medical affairs leaders
MAPS 2026 reflected an industry moment where three forces are converging:
-
- Therapy complexity is increasing based on scientific specialization, novel modalities, and precision approaches
-
- Stakeholders demand proof of real-world value to patients, payers, health systems, and, increasingly, internal leadership
-
- Technology is scaling faster than process and governance
The implications for medical affairs leaders are immediate. Teams must move beyond “doing more” into “changing more” and build the structures that make that change demonstrable, repeatable, and compliant.
Unlock our MAPS Americas 2026 insights
"*" indicates required fields
